Prospective Study of <i>Helicobacter pylori</i> Eradication Therapy in Stage I<sub>E</sub> High-Grade Mucosa-Associated Lymphoid Tissue Lymphoma of the Stomach

Chen, Li-Tzong; Lin, Jaw–Town; Shyu, Rong-Yaun; Jan, Chang-Ming; Chen, Chi‐Long; Chiang, I-Ping; Liu, Shiang-Ming; Su, Ih‐Jen; Cheng, Ann‐Lii

doi:10.1200/jco.2001.19.22.4245

Cited by 96 publications

(72 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent reports have shown that not a few patients with DLBL with or without areas of MALT lymphoma experienced disease remission after H. pylori eradication therapy. 12,31,32 In addition, 6 of 16 (38%) patients in Stage II 1 /IV in our series achieved CR, even though such tumors in advanced stage have been reported to rarely respond to eradication therapy. 9,11,12 The API2-MALT1 chimeric transcript mediated by t(11; 18) (q21; q21) translocation is one of the characteristic genetic alterations observed in a certain proportion of low-grade MALT lymphomas.…”

Section: Discussionmentioning

confidence: 90%

Long‐term clinical outcome of Helicobacter pylori eradication for gastric mucosa‐associated lymphoid tissue lymphoma with a reference to second‐line treatment

Nakamura

Matsumoto

Suekane

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe goals of the current study were to elucidate the long‐term outcome of Helicobacter pylori eradication therapy for gastric mucosa‐associated lymphoid tissue (MALT) lymphoma and to clarify the therapeutic efficacy of stomach‐conserving treatments for patients not responding to eradication therapy.METHODSNinety‐six patients with gastric MALT lymphoma, including 17 patients with areas of diffuse large B‐cell lymphoma, were treated by H. pylori eradication. Patients not responding to eradication therapy underwent either a gastrectomy, multiagent chemotherapy, oral monochemotherapy (OMC), or radiotherapy (RT). Predictive factors for the response to eradication therapy, overall survival (OS), and event‐free survival (EFS) were determined by the Kaplan–Meier analysis with the log‐rank test. The efficacy of second‐line treatment was compared between OMC and RT.RESULTSAfter eradication therapy, 62 (65%) patients achieved complete disease remission (CR). Transient histologic disease recurrence was confirmed in 4 (6.5%) of 62 patients with CR during the follow‐up (median, 37.5 months). The OS and EFS probabilities after 5 years were 0.96 and 0.80, respectively. Second‐line treatment was performed in 31 patients; gastrectomy in 4 patients, multiagent chemotherapy in 5 patients, OMC in 12 patients, and RT in 10 patients. There were no differences in the CR rate, OS, EFS, or toxicity between the OMC and RT groups.CONCLUSIONSH. pylori eradication therapy was an effective first‐line treatment for patients with gastric MALT lymphoma, which led to a favorable long‐term outcome. OMC and RT had an equivalent efficacy as a second‐line treatment in nonresponding patients to eradication therapy. Cancer 2005. © 2005 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 90%

Long‐term clinical outcome of Helicobacter pylori eradication for gastric mucosa‐associated lymphoid tissue lymphoma with a reference to second‐line treatment

Nakamura

Matsumoto

Suekane

et al. 2005

Cancer

View full text Add to dashboard Cite

show abstract

“…Therefore, DLBCL of the stomach were generally believed to be H pylori-independent, and unlikely to respond to antibiotic therapy. However, in addition to sporadic cases, one prospective study of 24 patients with DLBCL has shown that antibiotic therapy could also result in complete remission in patients with early stage gastric DLBCL with low grade components [15] . The same authors compared two prospective studies of the efficacy of H pylori eradication in the treatment of early-stage MALT lymphoma and DLBCL of the stomach and showed that the therapeutic efficacy of antibiotics for stage IE gastric high grade transformed MALT lymphoma was similar to their efficacy in stage IE low-grade lymphoma.…”

Section: Discussionmentioning

confidence: 99%

“…Eradication of H pylori is now well established as the first line treatment of gastric MALT lymphoma [8] and reports in the literature show 60%-80% remission rates [9][10][11] . In addition, several cases of complete remission of gastric DLBCL after H pylori eradication have been reported [12][13][14][15][16] . On the contrary, BL is known to require aggressive chemotherapy in order to induce remission, with systemic and intrathecal chemotherapy, and the impact of H pylori eradication on gastric BL has never been evaluated.…”

Section: Introductionmentioning

confidence: 99%

Complete remission of gastric Burkitt’s lymphoma aftereradication of Helicobacter pylori

Baumgaertner¹,

Copie‐Bergman²,

Lévy³

et al. 2009

WJG

View full text Add to dashboard Cite

Burkitt's lymphoma is a highly aggressive nonHodgkin lymphoma, often presenting in extra-nodal sites. It generally has a poor spontaneous outcome and needs aggressive treatment with systemic and intrathecal chemotherapy. Occurrence at the gastric site is rare. We report the case of a 39-year old woman who presented with a prominent ulcerated lesion of the antrum corresponding histologically to a Burkitt's lymphoma associated with Helicobacter pylori (H Ulcer healing and tumour regression with a complete histological response were obtained 8 wk after H pylori eradication. In spite of this complete remission, taking into account the high risk of recurrence, the patient received systemic and intrathecal chemotherapy. Two years later, the patient remained in complete remission. This is the first report of a gastric Burkitt's lymphoma responding to H pylori eradication. These findings raise the question of the potential role of H pylori in the pathogenesis of some gastric Burkitt's lymphomas, and show the importance of searching for and eradicating the bacteria in combination with conventional chemotherapy regimens.

show abstract

“…This view was recently challenged by the results of a study in which 10 of 15 patients with stage IE high-grade MALT lymphoma achieved complete histologic remission after anti-H. pylori therapy [105]. In an effort to identify which patients might respond to antibiotic therapy, Kuo et al [106] retrospectively evaluated the expression of CD86 (costimulatory molecule B7.2) and the infiltration by CD56…”

Section: High-grade Gastric Malt Lymphomamentioning

confidence: 99%

Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue

et al. 2006

View full text Add to dashboard Cite

show abstract

Prospective Study of Helicobacter pylori Eradication Therapy in Stage I_E High-Grade Mucosa-Associated Lymphoid Tissue Lymphoma of the Stomach

Abstract: These results suggest that high-grade transformation is not necessarily associated with the loss of H pylori dependence in early-stage MALT lymphomas of the stomach.

Cited by 96 publications

References 43 publications

Long‐term clinical outcome of Helicobacter pylori eradication for gastric mucosa‐associated lymphoid tissue lymphoma with a reference to second‐line treatment

Long‐term clinical outcome of Helicobacter pylori eradication for gastric mucosa‐associated lymphoid tissue lymphoma with a reference to second‐line treatment

Complete remission of gastric Burkitt’s lymphoma aftereradication of Helicobacter pylori

Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue

Contact Info

Product

Resources

About

Prospective Study of Helicobacter pylori Eradication Therapy in Stage IE High-Grade Mucosa-Associated Lymphoid Tissue Lymphoma of the Stomach

Abstract: These results suggest that high-grade transformation is not necessarily associated with the loss of H pylori dependence in early-stage MALT lymphomas of the stomach.

Cited by 96 publications

References 43 publications

Long‐term clinical outcome of Helicobacter pylori eradication for gastric mucosa‐associated lymphoid tissue lymphoma with a reference to second‐line treatment

Long‐term clinical outcome of Helicobacter pylori eradication for gastric mucosa‐associated lymphoid tissue lymphoma with a reference to second‐line treatment

Complete remission of gastric Burkitt’s lymphoma aftereradication of Helicobacter pylori

Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue

Contact Info

Product

Resources

About

Prospective Study of Helicobacter pylori Eradication Therapy in Stage I_E High-Grade Mucosa-Associated Lymphoid Tissue Lymphoma of the Stomach